Duration of vaccine efficacy against malaria: 5th year of follow-up in children vaccinated with RTS,S/AS02 in Mozambique (Q47859968)

6 February 2018

title

Duration of vaccine efficacy against malaria: 5th year of follow-up in children vaccinated with RTS,S/AS02 in Mozambique (English)

1 reference

6 February 2018

0 references

0 references

1 reference

Jahit Sacarlal

2

0 references

Pedro L. Alonso

7

object named as

Pedro L Alonso

1 reference

6 February 2018

3

John J Aponte

1 reference

6 February 2018

author name string

Joseph J Campo

1

1 reference

6 February 2018

Pedro Aide

4

1 reference

6 February 2018

Augusto J Nhabomba

5

1 reference

6 February 2018

Carlota Dobaño

6

1 reference

6 February 2018

language of work or name

English

0 references

publication date

11 March 2014

1 reference

6 February 2018

published in

Vaccine

1 reference

6 February 2018

volume

32

1 reference

6 February 2018

issue

19

1 reference

6 February 2018

page(s)

2209-2216

1 reference

6 February 2018

A research agenda for malaria eradication: vaccines

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.02.042

Long-term safety and efficacy of the RTS,S/AS02A malaria vaccine in Mozambican children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.02.042

Four-year efficacy of RTS,S/AS01E and its interaction with malaria exposure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.02.042

Evaluation of the persistence of vaccine-induced protection with human vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.02.042

First results of phase 3 trial of RTS,S/AS01 malaria vaccine in African children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.02.042

A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. RTS,S Malaria Vaccine Evaluation Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.02.042

GlaxoSmithKline Adjuvant Systems in vaccines: concepts, achievements and perspectives

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.02.042

Long-term efficacy and immune responses following immunization with the RTS,S malaria vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.02.042

Efficacy of recombinant circumsporozoite protein vaccine regimens against experimental Plasmodium falciparum malaria.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.02.042

Randomized, double-blind, phase 2a trial of falciparum malaria vaccines RTS,S/AS01B and RTS,S/AS02A in malaria-naive adults: safety, efficacy, and immunologic associates of protection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.02.042

Efficacy of RTS,S/AS02 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia: a randomised trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.02.042

Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.02.042

Efficacy of RTS,S/AS01E vaccine against malaria in children 5 to 17 months of age

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.02.042

Safety and immunogenicity of RTS,S/AS02D malaria vaccine in infants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.02.042

Safety of the RTS,S/AS02D candidate malaria vaccine in infants living in a highly endemic area of Mozambique: a double blind randomised controlled phase I/IIb trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.02.042

Four year immunogenicity of the RTS,S/AS02(A) malaria vaccine in Mozambican children during a phase IIb trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.02.042

Safety, immunogenicity and duration of protection of the RTS,S/AS02(D) malaria vaccine: one year follow-up of a randomized controlled phase I/IIb trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.02.042

Efficacy of RTS,S/AS01E malaria vaccine and exploratory analysis on anti-circumsporozoite antibody titres and protection in children aged 5-17 months in Kenya and Tanzania: a randomised controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.02.042

Insights into long-lasting protection induced by RTS,S/AS02A malaria vaccine: further results from a phase IIb trial in Mozambican children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.02.042

Duration of protection with RTS,S/AS02A malaria vaccine in prevention of Plasmodium falciparum disease in Mozambican children: single-blind extended follow-up of a randomised controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.02.042

Malaria in southern Mozambique: malariometric indicators and malaria case definition in Manhiça district

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.02.042

Validation of an enzyme-linked immunosorbent assay for the quantification of human IgG directed against the repeat region of the circumsporozoite protein of the parasite Plasmodium falciparum

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.02.042

Randomized, controlled trial of the long term safety, immunogenicity and efficacy of RTS,S/AS02(D) malaria vaccine in infants living in a malaria-endemic region

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.02.042

Intermittent preventive antimalarial treatment for Tanzanian infants: follow-up to age 2 years of a randomised, placebo-controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.02.042

Induction of Plasmodium falciparum-specific CD4+ T cells and memory B cells in Gabonese children vaccinated with RTS,S/AS01(E) and RTS,S/AS02(D)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.02.042

Impact of the RTS,S malaria vaccine candidate on naturally acquired antibody responses to multiple asexual blood stage antigens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.02.042

Efficacy of RTS,S malaria vaccines: individual-participant pooled analysis of phase 2 data

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.02.042

The relationship between RTS,S vaccine-induced antibodies, CD4⁺ T cell responses and protection against Plasmodium falciparum infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.02.042

10.1016/J.VACCINE.2014.02.042

7 January 2021

Identifiers

DOI

1 reference

6 February 2018

PubMed ID

24631081

1 reference

6 February 2018